New Research Poster Presentation 3.31: The Children's Problem Behavior and Aggression Questionnaire (CPBAQ) in Bipolar I Disorder: Results From a Four-Week, Randomized, Placebo-Controlled Ziprasidone Trial

Thursday, October 29, 2009 12:30 PM

Michelle Stewart, Ph.D., Clinical Development and Medical Affairs Specialty Care Business Unit Pfizer Global Development Headquarters, Pfizer Inc, New London, CT

Elizabeth Pappadopulos, Ph.D., Pfizer Inc, New York, NY

Yifan Huang, DrPH, Biostatistics, Pfizer Inc, New London, CT

Phillip Chappell, M.D., M.B.A., Pfizer Inc, New London, CT

Mary Bachinsky, M.S.C., Outcomes Research - Specialty Business Unit, Pfizer Inc, New London, CT

Mark Versavel, M.D., M.B.A., Ph.D., Pfizer Inc, New London, CT

Sally Olderbak, M.A., Psychology, University of Arizona, Tucson, AZ

See more of: New Research Poster Session 3
See more of: New Research Poster

		56th Annual Meeting Tentative Program Schedule
		Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

New Research Poster Presentation 3.31 The Children's Problem Behavior and Aggression Questionnaire (CPBAQ) in Bipolar I Disorder: Results From a Four-Week, Randomized, Placebo-Controlled Ziprasidone Trial

New Research Poster Presentation 3.31
The Children's Problem Behavior and Aggression Questionnaire (CPBAQ) in Bipolar I Disorder: Results From a Four-Week, Randomized, Placebo-Controlled Ziprasidone Trial